Return to study ST001009 main page

MB Sample ID: SA063466

Local Sample ID:ms6647-22
Subject ID:SU001048
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606

Select appropriate tab below to view additional metadata details:


Subject:

Subject ID:SU001048
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606

Factors:

Local Sample IDMB Sample IDFactor Level IDLevel ValueFactor Name
ms6647-22SA063466FL010862ControlGrouping
ms6647-22SA063466FL010862FemaleGender

Collection:

Collection ID:CO001042
Collection Summary:Tissue and blood donated from Cancer Cachexia Program at Ohio State University
Sample Type:Muscle

Treatment:

Treatment ID:TR001062
Treatment Summary:Cancer cachexia is a multi-factorial syndrome accompanying advanced cancer, with the most notable symptom being unintentional weight loss. Cachectic patients lose both adipose tissue and skeletal muscle, with skeletal muscle loss and its associated weakness contributing to the morbidity and mortality of these patients. Despite three decades of research into mechanisms driving muscle wasting due to cancer, to date, an approved pharmacological therapy to prevent or treat cancer cachexia is still lacking. Our laboratory focuses on cancer cachexia in patients with pancreatic cancer, as up to 85% of these patients experience weight loss. Cachexia often occurs early in the progression of pancreatic cancer, making clear that cachexia in these patients is not simply a result of end-stage disease. Further, with perhaps more than ΒΌ of all pancreatic cancer deaths resulting from muscle weakness as opposed to tumor burden, cachexia also significantly contributes to mortality due to pancreatic cancer. Because little progress has been made in improving treatment outcomes, addressing cancer-induced muscle wasting is perhaps the best strategy to prolong pancreatic cancer patient survival and increase patient quality of life. In an effort to better understand the mechanisms driving pancreatic cancer-induced muscle wasting, the Cancer Cachexia Program at Ohio State University has begun a Pancreatic Cancer Cachexia Tissue Bank. To date, over 130 patients undergoing attempted resection for pancreatic cancer or other abdominal surgeries have donated muscle and blood to our bank. A unique aspect of our tissue bank is our focus on patients eligible for resection. In contrast to other studies using patients with late-stage disease, our patients are not end-stage, as they are considered healthy enough to undergo a major operation.

Sample Preparation:

Sampleprep ID:SP001055
Sampleprep Summary:acyl carnitines concentrations using muscle tissue

Combined analysis:

Analysis ID AN001651
Analysis type MS
Chromatography type Reversed phase
Chromatography system Waters Acquity
Column Waters Acquity BEH C8 (150 x 2mm,1.7um)
MS Type ESI
MS instrument type Triple quadrupole
MS instrument name Thermo Quantiva QQQ
Ion Mode POSITIVE
Units nmol/vial

Chromatography:

Chromatography ID:CH001162
Instrument Name:Waters Acquity
Column Name:Waters Acquity BEH C8 (150 x 2mm,1.7um)
Chromatography Type:Reversed phase

MS:

MS ID:MS001526
Analysis ID:AN001651
Instrument Name:Thermo Quantiva QQQ
Instrument Type:Triple quadrupole
MS Type:ESI
Ion Mode:POSITIVE
  logo